• Vaccine Name: Alpha Fetoprotein Plasmid DNA Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007574
• Type: DNA vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Host Species as Laboratory Animal Model: Human
• AFP gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Description: A vaccine consisting of plasmid DNA encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05) (NCIT_C48373).

Human Response

• Host Strain: male, 80 years, Caucasian, HBV-/HCV-, with stage II HCC
• Vaccination Protocol: This patient was vaccinated intramuscularly between 11/2010-2/2011. Before vaccination, patients received 650 mg acetaminophen and 50 mg diphenhydramine. For each of the three monthly plasmid injections, 2.5 mg of pAFP and 2.5 mg of pGM-CSF were mixed together in the syringes before injection. For the dose of 109 pfu of AdVhAFP, the virus was diluted in sterile saline in the IMCPL before preparing the syringe for injection (Butterfield et al., 2014).
• Immune Response: This patient had a weak AFP-specific T cell response, a strong AdV-specific cellular response and recurred with an AFP-expressing HCC at nine months (Butterfield et al., 2014).